HUP0301335A2 - Combination of organic compounds - Google Patents

Combination of organic compounds

Info

Publication number
HUP0301335A2
HUP0301335A2 HU0301335A HUP0301335A HUP0301335A2 HU P0301335 A2 HUP0301335 A2 HU P0301335A2 HU 0301335 A HU0301335 A HU 0301335A HU P0301335 A HUP0301335 A HU P0301335A HU P0301335 A2 HUP0301335 A2 HU P0301335A2
Authority
HU
Hungary
Prior art keywords
disease
blood pressure
high blood
pharmaceutically acceptable
receptor antagonist
Prior art date
Application number
HU0301335A
Other languages
Hungarian (hu)
Inventor
Ronald Edward Steele
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0301335A2 publication Critical patent/HUP0301335A2/en
Publication of HUP0301335A3 publication Critical patent/HUP0301335A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya egy gyógyászati készítmény, amely (i) egyaldoszteron szintáz inhibitort vagy ennek gyógyászatilag elfogadhatósóját önmagában vagy (ii) egy AT1 receptor antagonistát vagy egy AT1receptor antagonista és egy diuretikum keverékét; vagy mindkét esetbena receptor antagonista gyógyászatilag elfogadható sóját és (iii) egygyógyászatilag elfogadható vivőanyagot tartalmaz, alkalmazása gyógyszer előállítására a következőcsoportok valamelyikébe tartozó betegség vagy tünet megelőzésére,kialakulásának késleltetésére vagy kezelésére: a) magas vérnyomás,pangásos szívbaj, veseelégtelenség /különösen a krónikus vesebaj, aperkután transzluminális érplasztika utáni és a szívkoszorúér bypasssebészet utáni szűkületkiújulás; b) ateroszklerózis, inzulinrezisztencia és X szindróma, 2. típusú cukorbetegség, elhízás,vesebaj, veseelégtelenség (különösen a krónikus vesebaj), apajzsmirigy csökkent működése, szívizom infarktus (MI) utáni túlélésiszakasz, a szívkoszorúér betegségek, időskori magas vérnyomás, családieredetű diszlipidémiás magas vérnyomás, a kollagéntermelés fokozódása,fibrózis, magas vérnyomás utáni helyreállítás (a keveréktöbbszöröződést gátló hatása alapján), valamennyi felsorolt betegségvagy állapot adott esetben magas vérnyomással összefüggésben és c)endoteliális diszfunkció adott esetben magas vérnyomássalösszefüggésben. ÓThe subject of the invention is a pharmaceutical preparation which contains (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof alone or (ii) an AT1 receptor antagonist or a mixture of an AT1 receptor antagonist and a diuretic; or in both cases contains a pharmaceutically acceptable salt of the receptor antagonist and (iii) contains a pharmaceutically acceptable carrier substance, its use for the production of medicine for the prevention, delaying or treatment of a disease or symptom belonging to one of the following groups: a) high blood pressure, congestive heart disease, kidney failure / especially chronic kidney disease, percutaneous stenosis recurrence after transluminal angioplasty and coronary artery bypass surgery; b) atherosclerosis, insulin resistance and syndrome X, type 2 diabetes, obesity, kidney disease, kidney failure (especially chronic kidney disease), decreased functioning of the thyroid gland, survival period after myocardial infarction (MI), coronary artery disease, senile hypertension, familial dyslipidemic hypertension , increase in collagen production, fibrosis, recovery after high blood pressure (based on the anti-multiplication effect of the mixture), all listed diseases or conditions in connection with high blood pressure and c) endothelial dysfunction in connection with high blood pressure. HE

HU0301335A 2000-04-12 2001-04-10 Combination of organic compounds HUP0301335A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19674200P 2000-04-12 2000-04-12
PCT/EP2001/004116 WO2001076574A2 (en) 2000-04-12 2001-04-10 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0301335A2 true HUP0301335A2 (en) 2003-08-28
HUP0301335A3 HUP0301335A3 (en) 2006-02-28

Family

ID=22726655

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301335A HUP0301335A3 (en) 2000-04-12 2001-04-10 Combination of organic compounds

Country Status (19)

Country Link
EP (1) EP1282410A2 (en)
JP (1) JP2003530343A (en)
KR (1) KR20020089437A (en)
CN (1) CN1422152A (en)
AR (1) AR032316A1 (en)
AU (2) AU2001273938B2 (en)
BR (1) BR0110079A (en)
CA (1) CA2405895A1 (en)
HU (1) HUP0301335A3 (en)
IL (1) IL152081A0 (en)
MX (1) MXPA02010091A (en)
NO (1) NO20024920L (en)
NZ (1) NZ521855A (en)
PE (1) PE20020082A1 (en)
PL (1) PL358459A1 (en)
RU (1) RU2002129569A (en)
SK (1) SK14612002A3 (en)
WO (1) WO2001076574A2 (en)
ZA (1) ZA200208204B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416152A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
ATE551056T1 (en) * 2002-12-27 2012-04-15 Takeda Pharmaceutical AGENT FOR INHIBITING BODY WEIGHT GAIN
SE0300988D0 (en) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
ITTO20040760A1 (en) * 2004-11-03 2005-02-03 Uni Degli Studi Del Piemonte USE OF A CORTICOSTEROID IN ASSOCIATION WITH OTHER ACTIVE PRINCIPLES FOR THE TREATMENT OF VASCULAR STENOSIS AND THE PREVENTION OF VASCULAR RESTENOSIS
AU2005318365B2 (en) * 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
MX2011012627A (en) 2009-05-28 2011-12-14 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CN107550914A (en) 2011-07-08 2018-01-09 诺华股份有限公司 The method that atherosclerosis is treated in high triglyceride object
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
KR20150119109A (en) 2013-02-14 2015-10-23 노파르티스 아게 Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CA2918074A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
PE20160991A1 (en) 2013-07-25 2016-10-15 Novartis Ag BIOCONJUGATES OF SYNTHETIC APELLIN POLYPEPTIDES
CU20170093A7 (en) 2015-01-23 2017-09-06 Novartis Ag CONJUGATES OF FATTY ACIDS AND SYNTHETIC APPEAL WITH GREATER HALF LIFE
JOP20190086A1 (en) 2016-10-21 2019-04-18 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
CA3040803A1 (en) 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
WO2019211394A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism
UY38485A (en) 2018-11-27 2020-06-30 Novartis Ag CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
CN113166204A (en) 2018-11-27 2021-07-23 诺华股份有限公司 Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
TW202333563A (en) 2021-11-12 2023-09-01 瑞士商諾華公司 Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252565A (en) * 1990-04-02 1993-10-12 Merrell Dow Pharmaceuticals Inc. Haloethyl-substituted steroid enzyme inhibitors
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd New bicyclic condensed imidazole derivative
CA2632790A1 (en) * 1996-07-22 1998-01-29 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
FR2766821A1 (en) * 1997-07-29 1999-02-05 Sanofi Sa 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
SI2322174T1 (en) * 1998-07-10 2015-12-31 Novartis Pharma Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes

Also Published As

Publication number Publication date
NO20024920L (en) 2002-11-27
BR0110079A (en) 2002-12-31
IL152081A0 (en) 2003-05-29
CN1422152A (en) 2003-06-04
RU2002129569A (en) 2004-03-27
NZ521855A (en) 2004-10-29
ZA200208204B (en) 2003-10-14
HUP0301335A3 (en) 2006-02-28
AR032316A1 (en) 2003-11-05
AU2001273938B2 (en) 2005-03-03
PL358459A1 (en) 2004-08-09
KR20020089437A (en) 2002-11-29
CA2405895A1 (en) 2001-10-18
SK14612002A3 (en) 2003-05-02
MXPA02010091A (en) 2003-02-12
AU7393801A (en) 2001-10-23
WO2001076574A2 (en) 2001-10-18
EP1282410A2 (en) 2003-02-12
WO2001076574A3 (en) 2002-04-25
PE20020082A1 (en) 2002-02-21
JP2003530343A (en) 2003-10-14
NO20024920D0 (en) 2002-10-11

Similar Documents

Publication Publication Date Title
HUP0301335A2 (en) Combination of organic compounds
Lo et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
Havale et al. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
Demuth et al. Type 2 diabetes—therapy with dipeptidyl peptidase IV inhibitors
ES2505665T3 (en) Procedure to lower blood glucose level in mammals
RU2006132668A (en) SYNERGETIC COMBINATIONS THAT CONTAIN A RENIN INHIBITOR, INTENDED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
AU2006287562B2 (en) Stabilized GLP-1 analogs
AU2003201274A1 (en) Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
Natsume et al. Characterization of the interaction of TZT‐1027, a potent antitumor agent, with tubulin
NO20082445L (en) Neuropeptide-2 receptor agonists
CR7074A (en) MERCAPTOACETYLAMIDA DERIVATIVES AND PROCESS FOR PREPARATION AND USE
SE9702457D0 (en) screening
NO20052496L (en) Selected CGRP antagonists, methods for their preparation and use thereof as drugs.
Schumacher Jr Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout
CA2460865A1 (en) Quinoline derivatives as neuropeptide y antagonists
WO2004062578A3 (en) Methods for reducing mortality associated with acute myocardial infarction
Erdal et al. Selective neuronal nitric oxide synthase inhibitors
Märki et al. Piperidine renin inhibitors: from leads to drug candidates
Costante et al. DPP-4 inhibitors: a patent review (2012–2014)
Kshirsagar et al. DPP IV inhibitors: successes, failures and future prospects
Agrawal et al. Chirality-A new era of therapeutics
ATE196768T1 (en) NEW 6-HYDROXY AND 6-OXO-ANDROSTANE COMPOUNDS WITH CARDIOACTIVITY AND PHARMACEUTICAL PREPARATIONS THEREOF
AU2006321471B2 (en) Composition for preventing or treating damages of the mucosa in the gastrointestinal tracts
RU2006122637A (en) 4-PHENYLIPIPERIDINE DERIVATIVES AS RENIN INHIBITORS
RU2006117790A (en) APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees